SARS-CoV-2 reinfection in a cancer patient with a defective neutralizing humoral response.
作者信息
Borgogna Cinzia, De Andrea Marco, Griffante Gloria, Lai Alessia, Bergna Annalisa, Galli Massimo, Zehender Gianguglielmo, Castello Luigi, Ravanini Paolo, Cattrini Carlo, Mennitto Alessia, Gennari Alessandra, Gariglio Marisa
机构信息
Virology Unit, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
Viral Pathogenesis Unit, Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy.
出版信息
J Med Virol. 2021 Dec;93(12):6444-6446. doi: 10.1002/jmv.27200. Epub 2021 Jul 20.
Abstract
摘要
相似文献
1
SARS-CoV-2 reinfection in a cancer patient with a defective neutralizing humoral response.
J Med Virol. 2021 Dec;93(12):6444-6446. doi: 10.1002/jmv.27200. Epub 2021 Jul 20.
2
Symptomatic reinfection of SARS-CoV-2 with spike protein variant N440K associated with immune escape.
J Med Virol. 2021 Jul;93(7):4163-4165. doi: 10.1002/jmv.26997. Epub 2021 Apr 13.
3
Protective immunity after recovery from SARS-CoV-2 infection.
Lancet Infect Dis. 2022 Jan;22(1):12-14. doi: 10.1016/S1473-3099(21)00676-9. Epub 2021 Nov 8.
4
Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster.
Emerg Microbes Infect. 2021 Dec;10(1):797-809. doi: 10.1080/22221751.2021.1913974.
5
SARS-CoV-2 Reinfection in a Healthcare Worker Despite the Presence of Detectable Neutralizing Antibodies.
Viruses. 2021 Apr 12;13(4):661. doi: 10.3390/v13040661.
6
Viral Shedding among Re-Positive Severe Acute Respiratory Syndrome Coronavirus-2 Positive Individuals in Republic of Korea.
Viruses. 2021 Oct 17;13(10):2089. doi: 10.3390/v13102089.
7
Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
EBioMedicine. 2021 Sep;71:103561. doi: 10.1016/j.ebiom.2021.103561. Epub 2021 Aug 27.
8
Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission.
Emerg Microbes Infect. 2021 Dec;10(1):152-160. doi: 10.1080/22221751.2021.1872352.
9
Correlates of protection from SARS-CoV-2 infection.
Lancet. 2021 Apr 17;397(10283):1421-1423. doi: 10.1016/S0140-6736(21)00782-0. Epub 2021 Apr 9.
10
Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection.
Viruses. 2021 Oct 5;13(10):2003. doi: 10.3390/v13102003.
引用本文的文献
1
Investigation of epidemiological and clinical characteristics of people infected with SARS-CoV-2 during the second pandemic of COVID-19 in Chengdu, China.
Front Public Health. 2024 May 1;12:1394762. doi: 10.3389/fpubh.2024.1394762. eCollection 2024.
2
Low Risk of SARS-CoV-2 Reinfection for Fully or Boosted mRNA Vaccinated Subjects in Sicily: A Population-Based Study Using Real-World Data.
Vaccines (Basel). 2023 Nov 26;11(12):1757. doi: 10.3390/vaccines11121757.
3
Humoral SARS-CoV-2 Immune Response in COVID-19 Recovered Vaccinated and Unvaccinated Individuals Related to Post-COVID-Syndrome.
Viruses. 2023 Feb 6;15(2):454. doi: 10.3390/v15020454.
4
Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS-CoV-2 mRNA-1237 vaccine in patients with solid tumors.
Mol Oncol. 2023 Apr;17(4):686-694. doi: 10.1002/1878-0261.13359. Epub 2022 Dec 30.
5
Who Is at Higher Risk of SARS-CoV-2 Reinfection? Results from a Northern Region of Italy.
Vaccines (Basel). 2022 Nov 8;10(11):1885. doi: 10.3390/vaccines10111885.
6
Effects of Antibody Responses to Pre-Existing Coronaviruses on Disease Severity and Complement Activation in COVID-19 Patients.
Microorganisms. 2022 Jun 10;10(6):1191. doi: 10.3390/microorganisms10061191.
7
Reinfection in patients with COVID-19: a systematic review.
Glob Health Res Policy. 2022 Apr 29;7(1):12. doi: 10.1186/s41256-022-00245-3.
8
Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients.
Blood Cancer J. 2022 Jan 18;12(1):8. doi: 10.1038/s41408-022-00608-6.
9
Persistence of Neutralizing Antibodies to SARS-CoV-2 in First Wave Infected Individuals at Ten Months Post-Infection: The UnIRSA Cohort Study.
Viruses. 2021 Nov 12;13(11):2270. doi: 10.3390/v13112270.
10
SARS-CoV-2 Reinfection Is a New Challenge for the Effectiveness of Global Vaccination Campaign: A Systematic Review of Cases Reported in Literature.
Int J Environ Res Public Health. 2021 Oct 19;18(20):11001. doi: 10.3390/ijerph182011001.
Zotero 插件